Allogene Therapeutics (ALLO) Return on Sales (2021 - 2026)
Allogene Therapeutics (ALLO) posted Return on Sales of 184.5% for Q4 2024, down 88.35% sequentially from 97.95% in Q3 2024, and down 14981.0% YoY from N/an in Q1 2024.
Allogene Therapeutics (ALLO) Return on Sales (2021 - 2026) Analysis & Trends
Allogene Therapeutics has reported Return on Sales for 4 years, with the latest figure at 184.5% in Q4 2024.
- Quarterly Return on Sales fell 14981.0% year-over-year to 184.5% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 184.5% (down 14477.0% YoY) and the FY2024 annual result came in at 117.09%, down 8264.0% from the prior year.
- Return on Sales slipped to 184.5% in Q4 2024 per ALLO's latest filing, from 97.95% in the prior quarter.
- Over five years, Return on Sales peaked at 0.0% in Q4 2021 and troughed at 184.5% in Q4 2024.
- A 4-year average of 48.23% and a median of 35.0% in 2024 frame the typical range for Return on Sales.
- The sharpest annual moves came in 2023 and 2024: Return on Sales jumped 4170 bps in 2023, then slumped 14981 bps in 2024.
- Over 4 years, Return on Sales stood at 0.0% in 2021, then tumbled by 9541221 bps to 38.67% in 2022, then gained by 10 bps to 34.69% in 2023, then tumbled by 432 bps to 184.5% in 2024.
- According to Business Quant data, Return on Sales over the past three periods registered 184.5%, 97.95%, and 66.78% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -0.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.31% |
| Dec 31, 2024 | -184.50% |
| Sep 30, 2024 | -97.95% |
| Jun 30, 2024 | -66.78% |
| Mar 31, 2024 | -35.31% |
| Dec 31, 2023 | -34.69% |
| Sep 30, 2023 | -41.61% |
| Jun 30, 2023 | -51.37% |
| Mar 31, 2023 | -33.34% |
| Dec 31, 2022 | -38.67% |
| Sep 30, 2022 | -83.31% |
| Jun 30, 2022 | -17.05% |
| Mar 31, 2022 | -20.90% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | -32.73% |
| Jun 30, 2021 | -33.39% |
| Mar 31, 2021 | -0.01% |